Navigation Links
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Date:1/26/2009

debt instruments that may be settled in cash upon conversion (including partial cash settlement) (FSP APB 14-1). Amgen expects the impact of the incremental non-cash interest expense associated with FSP APB 14-1 for 2009 to be in the range of $0.14 to $0.16 per share.

The company expects 2009 capital expenditures to be approximately $700 million.

Fourth Quarter Product and Pipeline Update

The Company provided updates on selected products and clinical programs.

Denosumab: The Company discussed the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer. The BLA submission contains data from six Phase 3 trials involving more than 11,000 patients. The Company has also submitted an application in Canada for these indications.

In the European Union, the Company has submitted an application for the approval of denosumab for treatment of PMO in women, and treatment of bone loss associated with hormone ablation therapy in patients with breast and prostate cancer.

Motesanib: The Company discussed the ongoing MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC). This trial was temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). The DMC also recommended that patients with squamous NSCLC immediately discontinue motesanib therapy but did not recommend discontinuation of motesanib therapy for patients with non-s
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... (PRWEB) May 27, 2015 Empowering ... to combat disease, Cubresa Inc. today announced its ... MR Compatible in-bore PET Scanner uses silicon photomultiplier ... single-purpose preclinical MRI machines from manufacturers like Bruker ... headquartered in Winnipeg, Canada. “This enables simultaneous PET ...
(Date:5/27/2015)... 27, 2015  Two years after its founding by ... citizen scientists, Oakland -based Counter Culture ... its mission to democratize science through a full-fledged community ... Photo - ... Based out of the new Omni ...
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
(Date:5/26/2015)... 26, 2015 The University of ... Max Planck Society establishing the Max Planck-University ... center will link two of the world's foremost research ... only the third Max Planck Centre in North America. ... for optics and photonics, was with university and ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3
... Dr. John McPherson, Platform Leader, Cancer Genomics and ... the Ontario Institute for Cancer Research (OICR) led a ... of the NEBNext(TM) DNA Sample Prep Reagents for use ... of the evaluation, "We are constantly striving for the ...
... The U.S. Environmental Protection Agency today outlined a ... nanomaterials may harm human health and the environment. ... and 100 nanometers. A nanometer is approximately 1/100,000 ... are currently used in hundreds of consumer products, ...
... ... , ... 2009 -- Counterfeit and adulterated food and drugs and advances in measurement science used to ... U.S. Pharmacopeial (USP) Convention. Held in Toronto, Canada, more than 300 people from 26 countries ...
Cached Biology Technology:Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2EPA announces research strategy to study nanomaterials 2Global Public Health the Focus of Scientific Conference 2Global Public Health the Focus of Scientific Conference 3
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... ball out of a scrum herpes virus can cause a ... have studied the spread of the disease among sumo wrestlers in ... could be even more pathogenic, according to an article published in ... "Scrumpox", or herpes gladiatorum , is a skin ...
... essential nutrient involved in vision, growth, cellular differentiation, and ... is chaperoned through the body on carrier proteins. ... funded by USDA and NIH, discovered that not only ... retinol-binding protein (RBP), elevated in obese individuals compared to ...
... William Metcalf and his collaborators have developed a way ... of malaria less expensive. Metcalf set ... group known as phosphonates, is made in nature by ... some phosphonates have antibiotic properties. Recently, Metcalf and his ...
Cached Biology News:Deadly rugby virus spreads in sumo wrestlers 2Don't forget the vitamin A when working with its carrier protein 2New way to make malaria medicine also first step in finding new antibiotics 2New way to make malaria medicine also first step in finding new antibiotics 3New way to make malaria medicine also first step in finding new antibiotics 4
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
...
... The SelectFX Alexa Fluor 488 Cytochrome ... reagents you need to detect cytochrome c ... anti-cytochrome c primary antibody and an ... Fluor 488 dye exhibits bright green fluorescence ...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: